Clinical trials: Diabetes Type I
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 1 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
The purpose of this study is to see whether IN-105 (oral insulin) is able to control increase in blood glucose after eating a meal.
- Trial name
- NCT01035801
- Testing
- IN-105, Insulin Lispro Injection
- Where
- 5 sites in India
- Volunteers
- 20 people
- Sponsor
- Biocon Limited
Diabetes, Diabetes Mellitus, Type 1
An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
This observational study is conducted in Africa. The aim of this observational study is to evaluate the efficacy and the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00738153
- Testing
- insulin detemir
- Where
- Morocco
- Volunteers
- 798 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00723411
- Testing
- rhGAD65
- Where
- 70 sites in Finland, France and 7 more
- Volunteers
- 334 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes Mellitus
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks…
- Trial name
- βETA PRESERVE (NCT07088068)
- Testing
- Teplizumab
- Where
- 202 sites in United States, Argentina and 18 more
- Volunteers
- 723 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.
- Trial name
- NCT01096940
- Testing
- AZD1656, simvastatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Safety and Tolerability of EGT0001474 in Healthy Volunteers
Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers
This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.
- Trial name
- NCT00854113
- Testing
- EGT0001474
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Theracos
Type 1 Diabetes Mellitus
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
The primary objectives of this study are to compare the difference in glycosylated hemoglobin (HbA1c) from baseline to Month 6 using Hylenex recombinant preadministration in continuous subcutaneous insulin infusion (CSII) versus…
- Trial name
- NCT01848990
- Testing
- Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro
- Where
- 39 sites in United States
- Volunteers
- 456 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections.
- Trial name
- STAR2 (NCT00530023)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric subjects with type 1 diabetes on insulin pump therapy.
- Trial name
- NCT02660827
- Testing
- Insulin Pump
- Where
- 11 sites in United States, Israel
- Volunteers
- 151 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Qingdao: Insulin Pump Follow-Up Program
The purpose of the study is to observe/ collect clinical data, subject users' feedback, and device data to better understand the real-life usage and acceptance of the 722 Pump in type 1 diabetes subjects,<18 years of age, and the…
- Trial name
- NCT02655666
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Insulin-Dependent
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Type 1
- Trial name
- NCT01973920
- Testing
- Oshadi Icp
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Oshadi Drug Administration
Type 1 Diabetes
ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash…
- Trial name
- ADAPT (NCT04235504)
- Testing
- MDI, AHCL
- Where
- 14 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
- Trial name
- CREATE-1 (NCT05626712)
- Testing
- CELZ-201 Administration, Control Group
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Creative Medical Technology Holdings Inc
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir compared to NPH insulin…
- Trial name
- NCT00184665
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 29 sites in Argentina, Australia and 8 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the trial drug in the body), and Safety of…
- Trial name
- NCT02938572
- Testing
- NNC0143-0406, Insulin Aspart
- Where
- Austria
- Volunteers
- 47 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients With Diabetes Using Levemir® FlexPen®
This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00670683
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 797 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Thailand.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00805922)
- Testing
- No treatment given
- Where
- Thailand
- Volunteers
- 2,342 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.